Seeyond’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$1.39M Buy
18,595
+6,326
+52% +$488K 0.13% 219
2022
Q3
$1.01M Sell
12,269
-2,843
-19% -$274K 0.12% 262
2022
Q2
$1.44M Sell
15,112
-1,720
-10% -$178K 0.16% 209
2022
Q1
$1.98M Sell
16,832
-2,586
-13% -$290K 0.2% 161
2021
Q4
$2.52M Sell
19,418
-76
-0.4% -$8.87K 0.23% 118
2021
Q3
$2.21M Sell
19,494
-2,840
-13% -$324K 0.21% 143
2021
Q2
$2.31M Sell
22,334
-167
-0.7% -$15.7K 0.22% 138
2021
Q1
$1.88M Buy
22,501
+3,498
+18% +$296K 0.19% 173
2020
Q4
$1.73M Sell
19,003
-735
-4% -$61K 0.18% 187
2020
Q3
$1.57M Buy
19,738
+296
+2% +$23.1K 0.17% 180
2020
Q2
$1.34M Buy
19,442
+6,071
+45% +$431K 0.15% 202
2020
Q1
$104K Sell
13,371
-9,783
-42% -$706K 0.01% 560
2019
Q4
$1.8M Sell
23,154
-1,290
-5% -$101K 0.19% 180
2019
Q3
$1.79M Buy
24,444
+14,883
+156% +$1.05M 0.19% 185
2019
Q2
$589K Sell
9,561
-13,935
-59% -$843K 0.06% 435
2019
Q1
$1.5M Sell
23,496
-2,004
-8% -$114K 0.14% 236
2018
Q4
$1.3M Buy
+25,500
New +$1.29M 0.18% 169

Other funds holding EW

Seeyond's EW Position: Q4 2022 in Review

Seeyond increased its Edwards Lifesciences (EW) stake by 52% in Q4 2022, buying an estimated $488K and bringing the position to 18,595 shares worth $1.39M. The position accounts for 0.13% of the portfolio, ranked #219.

Seeyond first reported a position in EW in Q4 2018 and has held it in 17 quarters since. The position peaked at $2.52M in Q4 2021. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2022.

  • Seeyond held 18,595 shares of Edwards Lifesciences worth $1.39M as of Q4 2022.
  • Seeyond bought 6,326 Edwards Lifesciences shares in Q4 2022, an estimated $488K.
  • Edwards Lifesciences made up 0.13% of Seeyond's portfolio in Q4 2022, its #219 holding.
  • Seeyond first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 17 quarters since.
  • Seeyond's Edwards Lifesciences position peaked at $2.52M in Q4 2021.
  • 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.

Based on Seeyond's 13F filing for Q4 2022, filed 13 Feb 2023.